Identification

Name
Sucralfate
Accession Number
DB00364  (APRD01238)
Type
Small Molecule
Groups
Approved
Description

A basic aluminum complex of sulfated sucrose. [PubChem]

Structure
Thumb
Synonyms
  • Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
  • Sucralfat
  • Sucralfate
  • Sucralfato
  • Sucralfatum
External IDs
CGA-6J / OS 202
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarafateSuspension1 g/10mLOralPhysicians Total Care, Inc.1996-03-12Not applicableUs
CarafateSuspension1 g/10mLOralAtlantic Biologicals Corps.1993-12-16Not applicableUs
CarafateTablet1 g/1OralAllergan1981-10-30Not applicableUs
CarafateSuspension1 g/10mLOralAllergan1993-12-16Not applicableUs
SucralfateSuspension1 g/10mLOralPharmaceutical Associates, Inc.2009-11-19Not applicableUs
SucralfateSuspension1 g/10mLOralCardinal Health2009-11-192017-10-31Us
SucralfateSuspension1 g/10mLOralVista Pharm, Inc.2012-08-16Not applicableUs
SucralfateTablet1 g/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs00591 0780 05 nlmimage10 b71d5bfa
SucralfateTablet1 g/1OralAphena Pharma Solutions Tennessee, Inc.1996-11-01Not applicableUs
SucralfateSuspension1 g/10mLOralCardinal Health2012-08-16Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sucralfate - Tab 1gTablet1 gOralApotex Corporation1994-12-31Not applicableCanada
Dom-sucralfateTablet1000 mgOralDominion Pharmacal1999-09-152016-10-25Canada
Nu-sucralfate - Tab 1gmTablet1 gOralNu Pharm Inc1994-12-312012-09-04Canada
PMS-sucralfateTablet1000 mgOralPharmascience Inc1999-02-23Not applicableCanada
SucralfateTablet1 g/1OralMesource Pharmaceuticals1996-11-11Not applicableUs
SucralfateTablet1 g/1OralPD-Rx Pharmaceuticals, Inc.1996-11-012020-03-31Us
SucralfateTablet1 g/1OralMc Kesson Contract Packaging1996-11-112017-09-30Us
SucralfateTablet1 g/1OralCardinal Health2010-01-082012-10-31Us55154 827920180907 15195 1cvqz74
SucralfateTablet1 g/1OralA-S Medication Solutions1996-11-11Not applicableUs50090 058220180913 8702 m5gre4
SucralfateTablet1 g/1OralAphena Pharma Solutions Tennessee, Inc.2017-09-25Not applicableUs
International/Other Brands
Antepsin (Orion) / Sucramal (Menarini) / Sucraxol (Medifarma) / Ulcogant (Merck)
Categories
UNII
XX73205DH5
CAS number
54182-58-0
Weight
Average: 1448.682
Monoisotopic: 1447.588619666
Chemical Formula
C11H28Al8O51S8
InChI Key
MNQYNQBOVCBZIQ-JQOFMKNESA-A
InChI
InChI=1S/C11H20O35S8.8Al.16H2O/c12-47(13,14)36-1-3-4(41-49(18,19)20)5(42-50(21,22)23)6(43-51(24,25)26)9(38-3)39-11(2-37-48(15,16)17)8(45-53(30,31)32)7(44-52(27,28)29)10(40-11)46-54(33,34)35;;;;;;;;;;;;;;;;;;;;;;;;/h3-10H,1-2H2,(H,12,13,14)(H,15,16,17)(H,18,19,20)(H,21,22,23)(H,24,25,26)(H,27,28,29)(H,30,31,32)(H,33,34,35);;;;;;;;;16*1H2/q;8*+3;;;;;;;;;;;;;;;;/p-24/t3-,4-,5+,6-,7+,8+,9+,10-,11-;;;;;;;;;;;;;;;;;;;;;;;;/m1......................../s1
IUPAC Name
[({[(2S,3R,4S,5R,6R)-4,5-bis({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-6-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]-2-{[(2R,3S,4S,5R)-3,4,5-tris({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-2-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]oxolan-2-yl]oxy}oxan-3-yl]oxy}sulfonyl)oxy]alumanediol
SMILES
O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O

Pharmacology

Indication

For the short-term treatment (up to 8 weeks) of active duodenal ulcer, as well as maintenance therapy for duodenal ulcer patients at reduced dosage (1 gram twice a day) after healing of acute ulcers. Also used for the short-term treatment of gastric ulcer.

Associated Conditions
Pharmacodynamics

Sucralfate is a prescription medication used to treat peptic ulcers. The current clinical uses of sucralfate are limited. It is effective for the healing of duodenal ulcers, but it is not frequently used for this since more effective drugs (e.g. proton pump inhibitors) have been developed. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. Chemically, sucralfate is a complex of the disaccharide sugar, sucrose, combined with sulfate and aluminum. In acidic solutions (e.g. gastric acid) it forms a thick paste that has a strong negative charge.

Mechanism of action

Although sucralfate's mechanism is not entirely understood, there are several factors that most likely contribute to its action. Sucralfate, with its strong negative charge, binds to exposed positively-charged proteins at the base of ulcers. In this way, it coats the ulcer and forms a physical barrier that protects the ulcer surface from further injury by acid and pepsin. It directly inhibits pepsin (an enzyme that breaks apart proteins) in the presence of stomach acid and binds bile salts coming from the liver via the bile thus protecting the stomach lining from injury caused by the bile acids. Sucralfate may increase prostaglandin production. Prostaglandins are known to protect the lining of the stomach and may also bind epithelial growth factor and fibroblast growth factor, both of which enhance the growth and repair mechanism of the stomach lining.

TargetActionsOrganism
APepsin
inhibitor
Human
AFibroblast growth factor 2
agonist
Human
APro-epidermal growth factor
inducer
Human
UFibrinogen alpha chain
antagonist
Human
UFibrinogen beta chain
antagonist
Human
UFibrinogen gamma chain
antagonist
Human
Absorption

Minimally absorbed from the gastrointestinal tract (up to 5% of the disaccharide component and less than 0.02% of aluminum).

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.

Half life

Not known.

Clearance
Not Available
Toxicity

Acute oral toxicity (LD50) in mice is >8000 mg/kg. There is limited experience in humans with overdosage of sucralfate. Sucralfate is only minimally absorbed from the gastrointestinal tract and thus risks associated with acute overdosage should be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Sucralfate.
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Sucralfate.
1alpha-Hydroxyvitamin D5The serum concentration of Sucralfate can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
3-Aza-2,3-Dihydrogeranyl DiphosphateSucralfate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Sucralfate.
AbacavirSucralfate may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbafunginSucralfate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcarboseAcarbose may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

References

Synthesis Reference

Nick V. Lazaridis, Moo K. Park, Yousry Sayed, "Method for preparing high potency sucralfate." U.S. Patent US4990610, issued March, 1973.

US4990610
General References
  1. Rees WD: Mechanisms of gastroduodenal protection by sucralfate. Am J Med. 1991 Aug 8;91(2A):58S-63S. [PubMed:1715673]
External Links
Human Metabolome Database
HMDB0014508
KEGG Compound
C07314
PubChem Compound
70789197
PubChem Substance
46508862
ChemSpider
26329506
ChEMBL
CHEMBL2029132
PharmGKB
PA451524
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Sucralfate
ATC Codes
A02BX02 — Sucralfate
AHFS Codes
  • 56:28.32 — Protectants
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentOesophagitis, Eosinophilic1
2Enrolling by InvitationSupportive CareGingivostomatitis / Hand, Foot, and Mouth Disease / Herpangina1
3CompletedSupportive CareHead and Neck Carcinoma / Mucositis1
4CompletedTreatmentAntimicrobial Drug Susceptibility Pattern / Etiological Organisms / Stress Ulcer Prophylaxis / Ventilator-associated Bacterial Pneumonia1
4CompletedTreatmentChronic Erosive Gastritis1
4CompletedTreatmentChronic Radiation Proctitis1
4CompletedTreatmentIndigestion1
Not AvailableRecruitingDiagnosticNon-erosive Reflux Disease (NERD) / Reflux, Gastroesophageal1
Not AvailableWithdrawnDiagnosticGastro-esophageal Reflux Disease (GERD) / Indigestion / Non Erosive Reflux Disease1

Pharmacoeconomics

Manufacturers
  • Axcan pharma us inc
  • Nostrum laboratories inc
  • Teva pharmaceuticals usa inc
Packagers
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • A-S Medication Solutions LLC
  • Axcan Pharma Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Giant Food Inc.
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Ivax Pharmaceuticals
  • Levista Inc.
  • Long Wing International Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Merckle GmbH
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nostrum Laboratories Inc.
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Prasco Labs
  • Precision Dose Inc.
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Prime European Therapeuticals SPA
  • Qingdao Pana Life Biochem Co. Ltd.
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Sanofi-Aventis Inc.
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Vistapharm Inc.
  • Warrick Pharmaceuticals Corp.
  • Watson Pharmaceuticals
  • Xactdose Inc.
Dosage forms
FormRouteStrength
TabletOral1000 mg
SuspensionOral1 g/10mL
TabletOral1 g/1
SuspensionOral100 mg
SuspensionOral1 g
TabletOral1 g
Prices
Unit descriptionCostUnit
Sucralfate 1 gm/10ml Suspension 10ml Cup13.99USD cup
Carafate 1 gm tablet1.45USD tablet
Sucralfate 1 gm tablet0.72USD tablet
Sucralfate powder0.6USD g
Sulcrate 1 g Tablet0.59USD tablet
Apo-Sucralfate 1 g Tablet0.31USD tablet
Novo-Sucralate 1 g Tablet0.31USD tablet
Nu-Sucralfate 1 g Tablet0.31USD tablet
Pms-Sucralfate 1 g Tablet0.31USD tablet
Carafate 1 gm/10ml Suspension0.24USD ml
Sulcrate Suspension Plus 200 mg/ml Suspension0.11USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsoluble in cold waterNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.714 mg/mLALOGPS
logP0.98ALOGPS
logP-5.6ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count35ChemAxon
Hydrogen Donor Count16ChemAxon
Polar Surface Area772.17 Å2ChemAxon
Rotatable Bond Count36ChemAxon
Refractivity175.09 m3·mol-1ChemAxon
Polarizability105.22 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7959
Blood Brain Barrier+0.8803
Caco-2 permeable-0.6433
P-glycoprotein substrateNon-substrate0.8087
P-glycoprotein inhibitor INon-inhibitor0.5656
P-glycoprotein inhibitor IINon-inhibitor0.986
Renal organic cation transporterNon-inhibitor0.8471
CYP450 2C9 substrateNon-substrate0.8611
CYP450 2D6 substrateNon-substrate0.8256
CYP450 3A4 substrateNon-substrate0.6233
CYP450 1A2 substrateNon-inhibitor0.772
CYP450 2C9 inhibitorNon-inhibitor0.8211
CYP450 2D6 inhibitorNon-inhibitor0.8865
CYP450 2C19 inhibitorNon-inhibitor0.7869
CYP450 3A4 inhibitorNon-inhibitor0.9828
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9328
Ames testNon AMES toxic0.5805
CarcinogenicityNon-carcinogens0.5356
BiodegradationNot ready biodegradable0.8432
Rat acute toxicity2.4219 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7937
hERG inhibition (predictor II)Non-inhibitor0.8793
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as disaccharide sulfates. These are disaccharides carrying one or more sulfate group on a sugar unit.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Disaccharide sulfates
Alternative Parents
O-glycosyl compounds / Ketals / Oxanes / Alkyl sulfates / Tetrahydrofurans / Oxacyclic compounds / Organic metal salts / Organic oxides / Hydrocarbon derivatives
Substituents
Disaccharide sulfate / Glycosyl compound / O-glycosyl compound / Ketal / Oxane / Alkyl sulfate / Organic sulfuric acid or derivatives / Tetrahydrofuran / Organic metal salt / Oxacycle
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

1. Pepsin
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Jensen SL, Funch Jensen P: Role of sucralfate in peptic disease. Dig Dis. 1992;10(3):153-61. [PubMed:1611711]
  2. Hollander D, Tarnawski A: The protective and therapeutic mechanisms of sucralfate. Scand J Gastroenterol Suppl. 1990;173:1-5. [PubMed:2190304]
  3. Peterson WL: Pathogenesis and therapy of peptic ulcer disease. J Clin Gastroenterol. 1990;12 Suppl 2:S1-6. [PubMed:1978840]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name
FGF2
Uniprot ID
P09038
Uniprot Name
Fibroblast growth factor 2
Molecular Weight
30769.715 Da
References
  1. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  2. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218]
  3. Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A, Jadus M: Growth factors: new 'endogenous drugs' for ulcer healing. Scand J Gastroenterol Suppl. 1995;210:15-8. [PubMed:8578198]
  4. Konturek SJ: Role of growth factors in gastroduodenal protection and healing of peptic ulcers. Gastroenterol Clin North Am. 1990 Mar;19(1):41-65. [PubMed:1970337]
  5. Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [PubMed:7948825]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Transmembrane receptor protein tyrosine kinase activator activity
Specific Function
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in ...
Gene Name
EGF
Uniprot ID
P01133
Uniprot Name
Pro-epidermal growth factor
Molecular Weight
133993.12 Da
References
  1. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218]
  2. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  3. Konturek SJ: Role of growth factors in gastroduodenal protection and healing of peptic ulcers. Gastroenterol Clin North Am. 1990 Mar;19(1):41-65. [PubMed:1970337]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Structural molecule activity
Specific Function
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function ...
Gene Name
FGA
Uniprot ID
P02671
Uniprot Name
Fibrinogen alpha chain
Molecular Weight
94972.455 Da
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Structural molecule activity
Specific Function
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function...
Gene Name
FGB
Uniprot ID
P02675
Uniprot Name
Fibrinogen beta chain
Molecular Weight
55927.9 Da
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Structural molecule activity
Specific Function
Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. I...
Gene Name
FGG
Uniprot ID
P02679
Uniprot Name
Fibrinogen gamma chain
Molecular Weight
51511.29 Da
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]

Drug created on June 13, 2005 07:24 / Updated on December 14, 2018 16:24